Hidradenitis suppurativa treatment experiences vary widely among patients; a new study highlights the need for personalised care and shared decision-making.

Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Study authors examined the relationship between the use of combined oral contraceptives and the onset of hidradenitis suppurativa.

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Hidradenitis Suppurativa (HS) is getting increased attention from dermatologists due to its frequent misdiagnosis and ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...

A recent review highlights how the Mediterranean diet can reduce inflammation and improve outcomes for chronic skin ...

Christopher J. Sayed, MD, reports on how the 2025 American Academy of Dermatology Annual Meeting was an exciting event for hidradenitis suppurativa (HS), with increasing buzz and interest in the ...

Treatment for hidradenitis suppurativa (HS) varies depending on the condition’s severity. Early HS can be manageable with medication, while more severe cases may require both medication and surgery.

Results showed a greater percentage of povorcitinib-treated patients achieved HiSCR50 compared with placebo at week 12. Topline data were announced from two pivotal phase 3 studies evaluating ...